Evidence map›Paper›PMID 42825928›Full record

Trial reportLasers in medical science2026

Treatment of hypertrophic scars using fractional CO2 laser alone in comparison with adding botulinium toxin either intalesional injection or assisted drug delivery.

Aya Fahim, Elham Saied, Marwa S El-Mesidy

Abstract readRandomized Controlled TrialComparative Study
In one paragraph

Trial report in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aya FahimKasr Al Ainy Faculty of Medicine, Department of Dermatology, Cairo University, Giza, Egypt.
Elham SaiedKasr Al Ainy Faculty of Medicine, Department of Dermatology, Cairo University, Giza, Egypt.
Marwa S El-MesidyKasr Al Ainy Faculty of Medicine, Department of Dermatology, Cairo University, Giza, Egypt. Marwa.elmesidy@kasralainy.edu.eg.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burns result in hypertrophic scarring, causing functional impairment, cosmetic and psychological concerns. Fractional CO₂ laser and botulinum, have shown promise in treatment. To evaluate the effectiveness of fractional laser treatment alone and combined with botulinum toxin A, delivered either through injections or topical application as fractional laser-assisted drug delivery in hypertrophic burn scar. A randomized comparative trial involving 16 patients with post-burn hypertrophic scars. The scar of each patient was divided into 3 sections: (1) fractional CO₂ laser combined with intralesional botulinum toxin type A, (2) fractional CO₂ laser monotherapy, and (3) fractional CO₂ laser with laser-assisted drug delivery of BTXA. Patients received three treatment sessions at monthly intervals, followed by a three-month follow up. Clinical outcomes were evaluated using the Vancouver Scar Scale. Intralesional BTXA demonstrated superior efficacy, achieving the greatest reductions in VSS (- 58.25%). Intralesional BTXA in combination with fractional CO₂ laser represents a highly effective treatment for post-burn hypertrophic scars, offering superior improvements in scar pliability, contour, and patient comfort compared with laser monotherapy or LADD. These findings support intralesional BTXA as the preferred therapeutic approach, while highlighting the potential of combination protocols for optimizing scar outcomes.

Indexed as

Botulinum Toxins, Type ACicatrix, HypertrophicLasers, GasAdultBurnsCombined Modality TherapyDrug Delivery SystemsFemaleHumansInjections, IntralesionalMaleMiddle AgedTreatment OutcomeYoung AdultBotulinum Toxins, Type ABTXAHypertrophic scarLADD

Identifiers

PMID42825928
PMCPMC13633153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.